Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
November 09, 2023 11:00 ET
|
Pharvaris N.V.
ZUG, Switzerland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023 06:50 ET
|
Pharvaris N.V.
Top-line data from Phase 2 CHAPTER-1 prophylactic study anticipated by YE2023Participated in an End-of-Phase 2 meeting with the FDA; initiation of global Phase 3 clinical study (RAPIDe-3) anticipated...
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
October 30, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
Pharvaris To Present at the APAAACI 2023 International Conference
October 13, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
Pharvaris To Present at the CIIC Fall 2023 Conference
October 04, 2023 07:34 ET
|
Pharvaris N.V.
ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
September 19, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris To Present at the 18th German Allergy Congress
September 06, 2023 06:51 ET
|
Pharvaris N.V.
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
August 23, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023 06:50 ET
|
Pharvaris N.V.
Enrollment completed in Phase 2 CHAPTER-1 prophylactic study; top-line data anticipated by YE2023Clinical hold lifted on deucrictibant for the on-demand treatment of HAE; initiation of global Phase 3...